FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
The planned study will enrol six to eight paediatric and adult patients with PSS in the US and Europe.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance